https://www.biopharmawatch.com/news/EVO/evotec-chief-scientific-officer-transition BiopharmaWatch en 2026-09-29T06:04:00.000Z Evotec Announces Chief Scientific Officer Transition https://www.biopharmawatch.com/news/PHAR/pharming-ceo-transition-announcement BiopharmaWatch en 2026-09-29T05:00:00.000Z Pharming announces CEO transition https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-azure-1-study-brelovitug BiopharmaWatch en 2026-09-29T00:34:00.000Z Resumen: Mirum Pharmaceuticals anuncia que se ha cumplido el criterio de valoración principal en el estudio de fase III AZURE-1 sobre brelovitug para tratar la hepatitis crónica por el virus delta https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-phase-3-azure-1-study BiopharmaWatch en 2026-09-29T00:34:00.000Z Mirum Pharmaceuticals gibt bekannt, dass der primäre Endpunkt in der Phase-3-Studie AZURE-1 zu Brelovitug bei chronischer Hepatitis-Delta-Virus-Infektion erreicht wurde https://www.biopharmawatch.com/news/BLTE/belite-bio-upcoming-medical-conferences BiopharmaWatch en 2026-09-29T00:00:00.000Z Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences https://www.biopharmawatch.com/news/IGC/how-sleep-supports-brain-health BiopharmaWatch en 2026-09-28T22:48:25.000Z How Sleep Supports Brain Health https://www.biopharmawatch.com/news/VIVI/tempramed-announces-upsized-offering BiopharmaWatch en 2026-09-28T21:49:00.000Z TempraMed Announces Upsize to Offering https://www.biopharmawatch.com/news/SMMT/astrazeneca-investment-summit-therapeutics BiopharmaWatch en 2026-09-28T21:30:00.000Z AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics https://www.biopharmawatch.com/news/AZN/eccogene-50-million-milestone-astrazeneca-phase-3 BiopharmaWatch en 2026-09-28T21:21:00.000Z Eccogene Receives $50 Million Milestone Payment from AstraZeneca Following Initiation of Global Phase 3 Program for Elecoglipron (AZD5004/ECC5004) https://www.biopharmawatch.com/news/PREV/preveceutical-announces-private-placement BiopharmaWatch en 2026-09-28T21:00:00.000Z PreveCeutical Announces Non-Brokered Private Placement https://www.biopharmawatch.com/news/DTC/defence-therapeutics-corporate-update-strategic-priorities BiopharmaWatch en 2026-09-28T21:00:00.000Z Defence Therapeutics Provides Corporate Update as Company Executes on Strategic Priorities https://www.biopharmawatch.com/news/ANGO/angiodynamics-fiscal-2027-first-quarter-results BiopharmaWatch en 2026-09-28T20:30:00.000Z AngioDynamics to Report Fiscal 2027 First Quarter Results on October 8, 2026 https://www.biopharmawatch.com/news/ALGN/align-technology-shift-happens-campaign BiopharmaWatch en 2026-09-28T20:30:00.000Z Align Technology Launches “SHIFT Happens” U.S. Campaign to Educate Adults About Lifelong Tooth Movement https://www.biopharmawatch.com/news/ALDX/aldeyra-regulatory-update-webcast-september-2026 BiopharmaWatch en 2026-09-28T20:30:00.000Z Aldeyra Therapeutics to Host Regulatory Update Webcast https://www.biopharmawatch.com/news/NYXH/nyxoah-nomme-liam-kelly-ceo BiopharmaWatch en 2026-09-28T20:30:00.000Z Nyxoah Nomme Liam Kelly au Poste de Chief Executive Officer https://www.biopharmawatch.com/news/NYXH/nyxoah-appoints-liam-kelly-ceo BiopharmaWatch en 2026-09-28T20:30:00.000Z Nyxoah Appoints Liam Kelly as Chief Executive Officer https://www.biopharmawatch.com/news/NAII/natural-alternatives-international-fiscal-2026-results BiopharmaWatch en 2026-09-28T20:30:00.000Z Natural Alternatives International, Inc. Announces Fiscal 2026 Q4 and YTD Results https://www.biopharmawatch.com/news/POCI/precision-optics-fy-2026-financial-results BiopharmaWatch en 2026-09-28T20:30:00.000Z Precision Optics Reports Fourth Quarter and Fiscal Year 2026 Financial Results https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-upsized-offerings-575-million BiopharmaWatch en 2026-09-28T20:30:00.000Z Viking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares of Common Stock and Convertible Senior Notes https://www.biopharmawatch.com/news/VSTM/verastem-oncology-ramp-201-study-results BiopharmaWatch en 2026-09-28T20:10:00.000Z Verastem Oncology Announces Publication in Gynecologic Oncology of Two-Year Median Follow-Up Data from RAMP 201 Study of AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer https://www.biopharmawatch.com/news/SIBN/si-bone-fda-clearance-ifuse-granite-onyx BiopharmaWatch en 2026-09-28T20:09:00.000Z SI-BONE Receives FDA 510(k) Clearance for iFuse Granite Onyx™, Extending Its Compromised Bone Franchise Beyond the Pelvis https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-patent-trofinetide-2023 BiopharmaWatch en 2026-09-28T20:05:00.000Z Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041 https://www.biopharmawatch.com/news/DFTX/definium-therapeutics-announces-new-employee-inducement-grants-20260928 BiopharmaWatch en 2026-09-28T20:01:00.000Z Definium Therapeutics Announces New Employee Inducement Grants https://www.biopharmawatch.com/news/TEVA/teva-fda-approval-degevma-biosimilar-xgeva BiopharmaWatch en 2026-09-28T20:00:00.000Z Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab) https://www.biopharmawatch.com/news/MOH/molina-healthcare-grants-genesee-county-sdoh BiopharmaWatch en 2026-09-28T19:00:00.000Z Molina Healthcare of Michigan and The MolinaCares Accord Award $160,000 in Grants to Genesee County-Area Organizations Addressing Social Determinants of Health https://www.biopharmawatch.com/news/MPH/medicure-completes-enrollment-mend-pnpo-trial BiopharmaWatch en 2026-09-28T18:00:00.000Z Medicure Announces Completion of Enrollment in Its MEND-PNPO Phase 3 Clinical Trial https://www.biopharmawatch.com/news/NRSN/neurosense-participate-roth-healthcare-conference BiopharmaWatch en 2026-09-28T16:43:00.000Z NeuroSense to Participate in the 5th Annual ROTH Healthcare Opportunities Conference https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-brelovitug-phase-3-study-success BiopharmaWatch en 2026-09-28T16:28:00.000Z Riassunto: Mirum Pharmaceuticals annuncia che brelovitug ha raggiunto l'endpoint primario dello studio di Fase 3 AZURE-1 per il trattamento del virus dell'epatite cronica Delta https://www.biopharmawatch.com/news/MIRM/samenvatting-mirum-pharmaceuticals-maakte-bekend-dat-het-primaire-eindpunt-bereikt BiopharmaWatch en 2026-09-28T16:28:00.000Z Samenvatting: Mirum Pharmaceuticals maakte bekend dat het primaire eindpunt is bereikt in de Fase 3 AZURE-1 studie van brelovitug bij chronische hepatitis delta-virus https://www.biopharmawatch.com/news/ALC/systane-pro-preservative-free-launch-canada BiopharmaWatch en 2026-09-28T14:15:00.000Z Introducing Systane® PRO PRESERVATIVE-FREE: Alcon’s Longest Lasting, Triple-Action Formula for up to 12 Hours of Dry Eye Symptom Relief https://www.biopharmawatch.com/news/NTHI/neonc-brain-cancer-pipeline-advances BiopharmaWatch en 2026-09-28T13:51:00.000Z Powerful NeOnc Brain Cancer Pipeline Advances https://www.biopharmawatch.com/news/NVO/novo-nordisk-s-share-repurchase-programme-20260928 BiopharmaWatch en 2026-09-28T13:50:00.000Z Novo Nordisk A/S - share repurchase programme https://www.biopharmawatch.com/news/ONCY/oncolytics-reo-033-colorectal-cancer-study-update BiopharmaWatch en 2026-09-28T13:30:00.000Z Oncolytics Biotech® Reports Accelerating Enrollment in Randomized REO 033 RAS-Mutant, MSS Colorectal Cancer Study https://www.biopharmawatch.com/news/ESYN/enersyn-global-nigeria-energy-investment-lagos-cng-project BiopharmaWatch en 2026-09-28T13:10:00.000Z EnerSyn Global Inc. Announces Second Nigeria Energy Investment: Lagos CNG Mother Station Project https://www.biopharmawatch.com/news/HYPD/hyperion-defi-d3-frontier-vault-launch BiopharmaWatch en 2026-09-28T13:06:00.000Z Hyperion DeFi Supports D3’s Frontier Vault Launch, Bringing Internet Domain Priority Access to the Hyperliquid Ecosystem https://www.biopharmawatch.com/news/PZZA/shareholders-who-lost-money-shares-acquired-papa-john-s-international-20260928 BiopharmaWatch en 2026-09-28T13:04:00.000Z Shareholders who lost money in shares of acquired Papa John's International, Inc. (NASDAQ: PZZA) should contact Wolf Haldenstein Immediately https://www.biopharmawatch.com/news/MMED/minimed-appoints-sheila-denton-general-counsel BiopharmaWatch en 2026-09-28T13:03:00.000Z MiniMed appoints Sheila Denton as General Counsel & Corporate Secretary https://www.biopharmawatch.com/news/CV/capsovision-fda-clearance-ai-highlights-capsocam-plus BiopharmaWatch en 2026-09-28T13:00:00.000Z CapsoVision Announces FDA Clearance of AI Highlights for CapsoCam Plus® https://www.biopharmawatch.com/news/LINC/lincoln-educational-services-class-action-lawsuit BiopharmaWatch en 2026-09-28T12:57:00.000Z Shareholders who lost money in shares of acquired Lincoln Educational Services Corporation (NASDAQ: LINC) should contact Wolf Haldenstein Immediately https://www.biopharmawatch.com/news/PALI/palisade-bio-presents-pali-2108-ueg-week-2026 BiopharmaWatch en 2026-09-28T12:50:00.000Z Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at UEG Week 2026 https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-acquisition-webster-equity-partners BiopharmaWatch en 2026-09-28T12:45:00.000Z Lifecore Biomedical to be Acquired by Webster Equity Partners https://www.biopharmawatch.com/news/GRI/gri-bio-ipf-summit-2026-insights BiopharmaWatch en 2026-09-28T12:40:00.000Z GRI Bio to Highlight Immune Modulation and Phase 2a Development Insights in IPF at the 10th IPF Summit https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-positive-preclinical-findings-sil204 BiopharmaWatch en 2026-09-28T12:30:00.000Z Silexion Therapeutics Reports Positive Preclinical Findings for SIL204, Demonstrating Key Mechanism for Endogenous Systemic Uptake in KRAS-Driven Cancers https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-cytisinicline-cheast-2026 BiopharmaWatch en 2026-09-28T12:30:00.000Z Achieve Life Sciences to Present 52-Week Cytisinicline Efficacy Data for Smoking and E-Cigarette Cessation at CHEST 2026 https://www.biopharmawatch.com/news/CARL/carlsmed-appoints-richard-heppenstall-cfo BiopharmaWatch en 2026-09-28T12:30:00.000Z Carlsmed Appoints Richard Heppenstall as Chief Financial Officer https://www.biopharmawatch.com/news/IGC/igc-pharma-completes-enrollment-phase-2-calma-trial BiopharmaWatch en 2026-09-28T12:23:06.000Z IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer’s Trial; Topline Results Expected Q4 2026 https://www.biopharmawatch.com/news/DARE/dare-bioscience-new-patent-dare-hpv-program BiopharmaWatch en 2026-09-28T12:20:00.000Z Dare Bioscience Announces New U.S. Patent Strengthening DARE-HPV Program as a Potential First FDA-Approved Pharmacologic Treatment for HPV Infection https://www.biopharmawatch.com/news/HYPR/hyperfine-expands-global-access-portable-brain-mri BiopharmaWatch en 2026-09-28T12:15:00.000Z Hyperfine Expands Global Access to Portable Brain MRI Technology Across Key Gulf Cooperation Council Healthcare Markets https://www.biopharmawatch.com/news/PBM/psyence-biomed-exclusive-ibogaine-license BiopharmaWatch en 2026-09-28T12:11:20.000Z Psyence BioMed Announces Exclusive U.S. Ibogaine Licence for Texas Ibogaine Research Corporation https://www.biopharmawatch.com/news/LABT/lakewood-amendex-nu-3-positive-data-diabetic-foot-ulcers BiopharmaWatch en 2026-09-28T12:02:00.000Z Lakewood-Amedex Biotherapeutics Announces Positive Data Against Recent Clinical Isolates from Infected Diabetic Foot Ulcers https://www.biopharmawatch.com/news/NTHI/neonc-technologies-fda-end-of-phase-1-meeting-ne0212 BiopharmaWatch en 2026-09-28T12:00:42.000Z NeOnc Technologies Announces FDA End of Phase 1 Meeting for NEO212 https://www.biopharmawatch.com/news/NKTR/nektar-rezpegaldesleukin-eadv-2026-presentations BiopharmaWatch en 2026-09-28T12:00:00.000Z Nektar Announces Three Oral Presentations for Rezpegaldesleukin at the European Academy of Dermatology & Venereology (EADV) Congress 2026 https://www.biopharmawatch.com/news/LNTH/lantheus-sparrow-phase-2-3-trial-prostate-cancer BiopharmaWatch en 2026-09-28T12:00:00.000Z Lantheus Announces First Patient Dosed in SPARROW Phase 2/3 Registrational Trial in Prostate Cancer https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-phase-3-azure-1-study-brelovitug BiopharmaWatch en 2026-09-28T12:00:00.000Z Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus https://www.biopharmawatch.com/news/TMO/thermo-fisher-earnings-conference-call-october-2026 BiopharmaWatch en 2026-09-28T12:00:00.000Z Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, October 21, 2026 https://www.biopharmawatch.com/news/NCEL/newcelx-attends-breakthrough-t1d-congress-2026 BiopharmaWatch en 2026-09-28T12:00:00.000Z NewCelX Management to Attend Breakthrough T1D Congress in Philadelphia, Advancing Its Mission to Develop a Cure for Type 1 Diabetes https://www.biopharmawatch.com/news/ALXO/alx-oncology-evorpacept-gastric-cancer-data BiopharmaWatch en 2026-09-28T12:00:00.000Z ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer https://www.biopharmawatch.com/news/FDMT/4dmt-phase-3-trial-4d-150-dme BiopharmaWatch en 2026-09-28T12:00:00.000Z 4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME https://www.biopharmawatch.com/news/KROS/keros-therapeutics-phase-2-dosing-rinvatercept-dmd BiopharmaWatch en 2026-09-28T12:00:00.000Z Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD https://www.biopharmawatch.com/news/HUMA/humacyte-expands-board-expertise-scott-coward-paul-kuznik BiopharmaWatch en 2026-09-28T12:00:00.000Z Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-expands-laboratory-capabilities BiopharmaWatch en 2026-09-28T12:00:00.000Z Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research https://www.biopharmawatch.com/news/ABBV/fda-approves-abbvie-juvmo-parkinsons-disease BiopharmaWatch en 2026-09-28T12:00:00.000Z U.S. FDA Approves AbbVie's JUVMO™ (tavapadon) for Parkinson's Disease https://www.biopharmawatch.com/news/PVLA/fda-funding-qtorin-rapamycin-microcystic-lymphatic-malformations BiopharmaWatch en 2026-09-28T11:30:09.000Z U.S. Food and Drug Administration Awards Additional Funding for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations https://www.biopharmawatch.com/news/CGC/canopy-growth-appoints-sebastian-bloete-germany-manager BiopharmaWatch en 2026-09-28T11:30:00.000Z Canopy Growth Appoints Sebastian Blöte as Country Manager for Germany https://www.biopharmawatch.com/news/BHVN/biohaven-bhv-1530-eortc-nci-aacr-symposium-2026 BiopharmaWatch en 2026-09-28T11:30:00.000Z Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026 https://www.biopharmawatch.com/news/IMRX/immuneering-2026-aacr-conference-atebimetinib-pancreatic-cancer BiopharmaWatch en 2026-09-28T11:30:00.000Z Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib’s Mechanisms Designed to Extend Survival in Pancreatic Cancer https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-appoints-yariv-houvras-cmo BiopharmaWatch en 2026-09-28T11:30:00.000Z Xilio Therapeutics Appoints Yariv J. Houvras, M.D., Ph.D. as Chief Medical Officer https://www.biopharmawatch.com/news/SCYX/scynexis-barda-contract-funding-scy-247 BiopharmaWatch en 2026-09-28T11:30:00.000Z SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247 https://www.biopharmawatch.com/news/CRVO/cervomed-neflamapimod-fda-removal-drug-limit BiopharmaWatch en 2026-09-28T11:30:00.000Z CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit https://www.biopharmawatch.com/news/MBRX/moleculin-announces-cardiac-safety-analysis-annamycin BiopharmaWatch en 2026-09-28T11:00:25.000Z Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine https://www.biopharmawatch.com/news/NAIA/naia-relief-alumni-perks-partnership-well-being-support BiopharmaWatch en 2026-09-28T11:00:00.000Z naia Relief Inc. Announces Strategic Partnership with Alumni-Perks to Expand Access to 24/7 Well-Being Support for Canadian University/College Alumni https://www.biopharmawatch.com/news/BRKR/bruker-advances-functional-proteomics-timsultra-timsomni BiopharmaWatch en 2026-09-28T11:00:00.000Z Bruker Advances Functional Proteomics with Novel timsUltra AIP and timsOmni Workflows for Drug Discovery & Development and Disease Biology Research https://www.biopharmawatch.com/news/ANTX/antx-funding-extension-tuberculosis-research-gsk BiopharmaWatch en 2026-09-28T11:00:00.000Z AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK https://www.biopharmawatch.com/news/CSTL/tissuecypher-study-management-non-dysplastic-barretts-esophagus BiopharmaWatch en 2026-09-28T11:00:00.000Z New Study Shows That TissueCypher® Changed Management at an Expert Surgery Center in 90% of Patients With Non-Dysplastic Barrett's Esophagus https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-banyan-trial-als-foralumab BiopharmaWatch en 2026-09-28T11:00:00.000Z Tiziana Life Sciences Announces First Participants Dosed in ALS BANYAN Clinical Trial of Intranasal Foralumab https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-virtual-kol-event-denifanstat-update BiopharmaWatch en 2026-09-28T11:00:00.000Z Sagimet Biosciences to Host Virtual KOL Event, “Denifanstat Update: 52-Week Data from Phase 3 Open-Label Extension in China and Planned AURORA Phase 3 Clinical Trial in US” on September 30, 2026 https://www.biopharmawatch.com/news/BLSM/blossomhill-therapeutics-bh-501284-aacr-conference BiopharmaWatch en 2026-09-28T11:00:00.000Z BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer https://www.biopharmawatch.com/news/ARVN/arvinas-phase-1-2-trial-arv-6723 BiopharmaWatch en 2026-09-28T11:00:00.000Z Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-launches-impavido-capsules BiopharmaWatch en 2026-09-28T10:50:00.000Z Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO® (miltefosine) Capsules https://www.biopharmawatch.com/news/PFE/pfizer-cancer-care-esmo-2026 BiopharmaWatch en 2026-09-28T10:45:00.000Z Pfizer Advances Today’s Cancer Care and Tomorrow's Potential Breakthroughs at ESMO https://www.biopharmawatch.com/news/PFE/pfizer-advances-cancer-care-esmo-2026 BiopharmaWatch en 2026-09-28T10:45:00.000Z Pfizer Advances Today’s Cancer Care and Tomorrow's Potential Breakthroughs at ESMO https://www.biopharmawatch.com/news/MRK/merck-exclusive-license-agreement-sci-brunch-spr2015 BiopharmaWatch en 2026-09-28T10:45:00.000Z Merck Enters into Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015, an Investigational Oral KRAS G12D (ON) Inhibitor https://www.biopharmawatch.com/news/ACET/adicet-bio-prula-cel-safety-efficacy-data-sle BiopharmaWatch en 2026-09-28T10:45:00.000Z Adicet Bio Announces Positive Safety and Efficacy Data from Prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis https://www.biopharmawatch.com/news/KOD/zenkuda-tabirafusp-ted-daybreak-trial-wamd BiopharmaWatch en 2026-09-28T10:30:00.000Z Zenkuda and tabirafusp-ted Meet Primary Endpoints in Pivotal DAYBREAK Trial in wAMD, with Zenkuda Demonstrating a Potential New Standard-of-Care Profile with Strong Immediacy and Sustained Clinical Effect with Majority of Patients on 24-week Dosing Interval Using Strict Treat-to-Dryness Real World Retreatment Criteria. https://www.biopharmawatch.com/news/WELL/well-health-wellstar-tsxv-listing-approval BiopharmaWatch en 2026-09-28T10:00:00.000Z WELL Health Subsidiary WELLSTAR Announces Conditional Approval for TSXV Listing and Files Filing Statement https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-dr-michael-white-promotion BiopharmaWatch en 2026-09-28T10:00:00.000Z IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development https://www.biopharmawatch.com/news/ZYME/zymeworks-theravance-biopharma-acquisition-financial-guidance BiopharmaWatch en 2026-09-28T10:00:00.000Z Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition https://www.biopharmawatch.com/news/MNOV/medicinova-topline-results-mn-001-natg-202-trial BiopharmaWatch en 2026-09-28T10:00:00.000Z MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast) https://www.biopharmawatch.com/news/SNZZF/senzime-financing-oem-expansion-profitability BiopharmaWatch en 2026-09-28T09:20:00.000Z Senzime Strengthens Financing to Support Strategic OEM Expansion and Path to Profitability https://www.biopharmawatch.com/news/NNVC/clinical-trial-nv-387-ebola-enrollment-dosing BiopharmaWatch en 2026-09-28T08:45:00.000Z Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricides https://www.biopharmawatch.com/news/YI/111-inc-establishes-special-committee BiopharmaWatch en 2026-09-28T08:30:00.000Z 111, Inc. Announces Establishment of the Special Committee https://www.biopharmawatch.com/news/COSM/cosmos-health-cmo-pipeline-revenue-growth BiopharmaWatch en 2026-09-28T08:00:00.000Z Cosmos Health's Contract Manufacturing Division Surpasses $20 Million in Implied Revenue and $18 Million in Implied Gross Profit Across Its Record 32.7 Million-Unit Production Pipeline https://www.biopharmawatch.com/blog/biotech-catalysts-to-watch-week-of-2026-09-28 BiopharmaWatch en 2026-09-28T07:15:32.098Z IGALMI PDUFA for Agitation in Bipolar Disorder: Biotech Catalysts Sep 28, 2026 https://www.biopharmawatch.com/news/STAA/staars-consumer-survey-vision-correction-germany BiopharmaWatch en 2026-09-28T07:00:00.000Z Verbraucherumfrage von STAAR Surgical: 71 Prozent der Deutschen möchten auf Sehhilfen verzichten, kennen aber ihre Alternativen nicht https://www.biopharmawatch.com/news/TMO/thermo-fisher-evosep-reseller-agreement BiopharmaWatch en 2026-09-28T07:00:00.000Z Thermo Fisher Scientific and Evosep Enter Reseller Agreement for Evosep Eno https://www.biopharmawatch.com/news/MEDS/datameds-ai-tollo-health-launch-health-lives-here-app BiopharmaWatch en 2026-09-28T06:00:00.000Z DataMeds AI and Tollo Health Announce Launch of 'Health Lives Here' Mobile Application https://www.biopharmawatch.com/news/DXCM/dexcom-report-easd-2026-diabetes-care-opportunity BiopharmaWatch en 2026-09-28T06:00:00.000Z Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care https://www.biopharmawatch.com/news/IVA/inventiva-reports-2026-first-half-financial-results BiopharmaWatch en 2026-09-28T06:00:00.000Z Inventiva Reports Unaudited 2026 First-Half Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/QGEN/qiagen-fda-clearance-qiastat-dx-bacteria-panel BiopharmaWatch en 2026-09-28T05:30:00.000Z QIAGEN Completes U.S. QIAstat-Dx Bloodstream Infection Portfolio With FDA Clearance of New Bacteria Detection Panel https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-2026-half-year-results-update BiopharmaWatch en 2026-09-28T05:00:00.000Z Addex Therapeutics Reports 2026 Half-Year Results and Provides Corporate Update https://www.biopharmawatch.com/news/PTN/palatin-fiscal-year-2026-results-business-update BiopharmaWatch en 2026-09-28T00:00:00.000Z Palatin Reports Fiscal Year 2026 Financial Results and Provides Business Update Programs are focused on rare obesity disorders associated with the melanocortin 4 receptor (MC4R) pathway, including hypothalamic obesity,... https://www.biopharmawatch.com/news/LLY/lilly-change-course-commitment-diabetes-obesity-lmics BiopharmaWatch en 2026-09-28T00:00:00.000Z Lilly launches the Lilly Change the Course Commitment, aiming to address treatment gaps in diabetes and obesity in LMICs Through this commitment, Lilly aims to expand access to its innovative diabetes and obesity medicines to as many people in resource-limited settings, ... https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-investor-call-azure-1-study BiopharmaWatch en 2026-09-27T21:00:00.000Z Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026 https://www.biopharmawatch.com/news/ARAY/accuray-samsung-neurologica-collaboration-cyberknife BiopharmaWatch en 2026-09-27T15:15:00.000Z Accuray and Samsung NeuroLogica Advance Volumetric Imaging Collaboration for the Accuray CyberKnife® Platform